Azithromycin Placebo

Approved

WWake Forest University Health Sciences

Azithromycin Placebo is one of 2 therapeutic programs targeting Cervical Insufficiency. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cervical InsufficiencyNot yet recruiting

Cervical InsufficiencyApproved

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Cervical Insufficiency

#DrugCompanyPhaseTrials

Ancef

BBaxter Healthcare Corporation

Approved

1 2

Azithromycin Placebo

WWake Forest University Health Sciences

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedNot yet recruiting

Cervical Insufficiency

NCT07608562

Clinical

Trials by Indication[1]

Cervical Insufficiency1 trial

Evaluating Azithromycin Prophylaxis and Mycoplasma Prevalence in High-Risk Pregnancies Requiring Cerclage: A Prospective Cohort Study

Not yet recruiting·WWake Forest University Health Sciences·Approved·NCT07608562·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Azithromycin Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Azithromycin Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: WWake Forest University Health Sciences

Azithromycin Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Cervical Insufficiency1 trial

References

Drug Info

Quick Facts

Related News